Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Research & Development: 2016-2025

Historic Research & Development for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to $131.1 million.

  • Summit Therapeutics' Research & Development rose 247.51% to $131.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $441.8 million, marking a year-over-year increase of 255.66%. This contributed to the annual value of $150.8 million for FY2024, which is 153.53% up from last year.
  • Summit Therapeutics' Research & Development amounted to $131.1 million in Q3 2025, which was down 36.98% from $208.0 million recorded in Q2 2025.
  • In the past 5 years, Summit Therapeutics' Research & Development registered a high of $208.0 million during Q2 2025, and its lowest value of $5.4 million during Q4 2022.
  • Its 3-year average for Research & Development is $64.6 million, with a median of $37.7 million in 2024.
  • In the last 5 years, Summit Therapeutics' Research & Development dropped by 10.12% in 2023 and then skyrocketed by 575.44% in 2025.
  • Over the past 4 years, Summit Therapeutics' Research & Development (Quarterly) stood at $5.4 million in 2022, then skyrocketed by 360.71% to $24.8 million in 2023, then spiked by 107.07% to $51.4 million in 2024, then skyrocketed by 247.51% to $131.1 million in 2025.
  • Its last three reported values are $131.1 million in Q3 2025, $208.0 million for Q2 2025, and $51.3 million during Q1 2025.